content: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  
  
  Date  of  Report  (Date  of earliest event reported)   OCTOBER 19, 1995 ENZON,
  
  INC.
  
                    (Exact name  of  registrant  as  specified  in  its charter)
  
  
  
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  
  
  Registrant's telephone number, including area code    (908) 980-4500
  
  
  
  
       (Former name or former address, if changed since last report)
  
  
  
  
  <PAGE>
  
  ITEM 5.  OTHER EVENTS
  
       Enzon,  Inc.  ("Enzon"  or  the  "Company") has been advised by Sanofi
  Winthrop,  Inc. that the Phase III clinical  trial  of  DISMUTEC<trademark>
  (pegorgotein) in patients with severe closed head injury has been evaluated
  and fails to  show  a  statistically  significant  difference  between  the
  treatment  group  and  the  control group.  DISMUTEC, the enzyme superoxide
  dismutase modified with Enzon's  proprietary PEG-technology, is designed to
  decrease tissue injury caused by ischemia  or  trauma in severe closed head
  injury   patients.   Through  modification  with  Enzon's   PEG-technology,
  DISMUTEC exhibited longer circulating half-life and reduced immunogenicity;
  however,  the   drug   showed  insufficient  therapeutic  effect  for  this
  indication.  The Company believes the results of the clinical trial have no
  immediate impact on the  Company  from an earnings or cash flow perspective
  and that these results do not reflect  adversely  on  the  Company's  other
  products or PEG-technology.
  
  
  
  <PAGE>
  
                              SIGNATURES
  
  
       Pursuant  to  the requirements of the Securities Exchange Act of 1934,
  
  the Registrant has duly  caused  this  report to be signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  
  
  
  Dated:  October 20, 1995
  
  
  
  
                                                ENZON, INC.
                                               (Registrant)
  
                             By:   /S/ KENNETH J. ZUERBLIS  Kenneth J. Zuerblis
                                       Vice President, Finance
                                       (Principal Financial and
                                       Accounting Officer)
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 2600}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "95584963"}, "business-address": {"street1": "40 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  Date  of  Report  (Date  of earliest event reported)   OCTOBER 19, 1995 ENZON,
  
  INC.
  
                    (Exact name  of  registrant  as  specified  in  its charter)
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  Registrant's telephone number, including area code    (908) 980-4500
  
       (Former name or former address, if changed since last report)
  ITEM 5.  OTHER EVENTS
  
       Enzon,  Inc.  ("Enzon"  or  the  "Company") has been advised by Sanofi
  Winthrop,  Inc. that the Phase III clinical  trial  of  DISMUTEC
  (pegorgotein) in patients with severe closed head injury has been evaluated
  and fails to  show  a  statistically  significant  difference  between  the
  treatment  group  and  the  control group.  DISMUTEC, the enzyme superoxide
  dismutase modified with Enzon's  proprietary PEG-technology, is designed to
  decrease tissue injury caused by ischemia  or  trauma in severe closed head
  injury   patients.   Through  modification  with  Enzon's   PEG-technology,
  DISMUTEC exhibited longer circulating half-life and reduced immunogenicity;
  however,  the   drug   showed  insufficient  therapeutic  effect  for  this
  indication.  The Company believes the results of the clinical trial have no
  immediate impact on the  Company  from an earnings or cash flow perspective
  and that these results do not reflect  adversely  on  the  Company's  other
  products or PEG-technology.
  SIGNATURES
  
       Pursuant  to  the requirements of the Securities Exchange Act of 1934,
  
  the Registrant has duly  caused  this  report to be signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  Dated:  October 20, 1995
  
                                                ENZON, INC.
                                               (Registrant)
  
                             By:   /S/ KENNETH J. ZUERBLIS  Kenneth J. Zuerblis
                                       Vice President, Finance
                                       (Principal Financial and
                                       Accounting Officer)